ORL-1: An awkward child of the opioid receptor family

Neuroscientist

Volumn 4, Issue 3, 1998, Pages 172-184

  Zaki, Paulette A ^a   Evans, Chris J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiopioid; Dynorphin; Nociceptin; Nociception; Opioid receptor; ORL 1; Orphan; Orphanin FQ

Indexed keywords

DELTA OPIATE RECEPTOR; DYNORPHIN; KAPPA OPIATE RECEPTOR; MORPHINE; MU OPIATE RECEPTOR; NALOXONE; NOCICEPTIN; OPIATE RECEPTOR; ORL 1 RECEPTOR; UNCLASSIFIED DRUG;

ALLODYNIA; ANIMAL CELL; ANIMAL EXPERIMENT; DOSE RESPONSE; DRUG MECHANISM; FEMALE; HYPERALGESIA; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRATHECAL DRUG ADMINISTRATION; MALE; MOLECULAR CLONING; MOUSE; NOCICEPTIVE STIMULATION; NONHUMAN; PROTEIN ISOLATION; RAT; REVIEW; TAIL FLICK TEST;

EID: 0031835587     PISSN: 10738584     EISSN: None     Source Type: Journal    
DOI: 10.1177/107385849800400313     Document Type: Review

References (110)

1. Dhawan BN, Cesselin F, Raghubir R, et al. International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol Rev 1996;48:567-592.
2. Simon DL. Rapid opioid detoxification using opioid antagonists: history, theory and the state of the art. J Addict Dis 1997;16: 103-122.
3. Goldstein A, Naidu A. Multiple opioid receptors: ligand selectivity profiles and binding site signatures. Mol Pharmacol 1989; 36:265-272.
4. Evans CJ, Hammond DL, Frederickson RCA. The opioid peptides. In: Pasternak GW, editor. The opiate receptors. Clifton (NJ): Humana Press; 1988. p. 23-71.
5. Satoh M, Minami M. Molecular pharmacology of the opioid receptors. Pharmacol Ther 1995;68:343-364.
6. Kieffer BL. Recent advances in molecular recognition and signal transduction of active peptides: receptors for opioid peptides. Cell Mol Neurobiol 1995;15:615-635.
7. Minami M, Satoh M. Molecular biology of the opioid receptors: structures, functions and distributions. Neurosci Res 1995;23: 121-145.
8. Meng F, Taylor LP, Hoversten MT, et al. Moving from the orphanin FQ receptor to an opioid receptor using four point mutations. J Biol Chem 1996;271:32016-32020.
9. Mollereau C, Moisand C, Butour JL, Parmentier M, Meunier JC. Replacement of Gln280 by His in TM6 of the human ORL1 receptor increases affinity but reduces intrinsic activity of opioids. FEBS Lett 1996;395:17-21.
10. Pan YX, Xu J, Ryan-Moro J, et al. Dissociation of affinity and efficacy in KOR-3 chimeras. FEBS Lett 1996;395:207-210.
11. Nishi M, Takeshima H, Mori M, Nakagawara K, Takeuchi T. Structure and chromosomal mapping of genes for the mouse kappa-opioid receptor and an opioid receptor homologue (MOR-C). Biochem Biophys Res Commun 1994;205:1353-1357.
12. Wang JB, Johnson PS, Imai Y, et al. cDNA cloning of an orphan opiate receptor gene family member and its splice variant. FEBS Lett 1994;348:75-79.
13. Halford WP, Gebhardt BM, Carr DJ. Functional role and sequence analysis of a lymphocyte orphan opioid receptor. J Neuroimmunol 1995;59:91-101.
14. Wick MJ, Minnerath SR, Lin X, Elde R, Law PY, Loh HH. Isolation of a novel cDNA encoding a putative membrane receptor with high homology to the cloned mu, delta, and kappa opioid receptors. Mol Brain Res 1994;27:37-44.
15. 3-related opioid receptor. Mol Pharmacol 1995;47:1180-1188.
16. King MA, Rossi GC, Chang AH, Williams L, Pasternak GW. Spinal analgesic activity of orphanin FQ/nociceptin and its fragments. Neurosci Lett 1997;223:113-116.
17. Pasternak GW. Pharmacological mechanisms of opioid analgesics. Clin Neuropharmacol 1993;16:1-18.
18. Mollereau C, Parmentier M, Mailleux P, et al. ORL1, a novel member of the opioid receptor family: cloning, functional expression and localization. FEBS Lett 1994;341:33-38.
19. Bunzow JR, Saez C, Mortrud M, et al. Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a mu, delta or kappa opioid receptor type. FEBS Lett 1994;347:284-288.
20. Chen Y, Fan Y, Liu J, et al. Molecular cloning, tissue distribution and chromosomal localization of a novel member of the opioid receptor gene family. FEBS Lett 1994;347:279-283.
21. Fukuda K, Kato S, Mori K, et al. cDNA cloning and regional distribution of a novel member of the opioid receptor family. FEBS Lett 1994;343:42-46.
22. Wick MJ, Minnerath SR, Roy S, Ramakrishnan S, Loh HH. Expression of alternate forms of brain opioid 'orphan' receptor mRNA in activated human peripheral blood lymphocytes and lymphocytic cell lines. Mol Brain Res 1995;32:342-347.
23. Anton B, Fein J, To T, Li X, Silberstein L, Evans CJ. Immunohistochemical localization of ORL-1 in the central nervous system of the rat. J Comp Neurol 1996;368:229-251.
24. Zaki PA, Bilsky EJ, Vanderah TW, Lai J, Evans CJ, Porreca F. Opioid receptor types and subtypes: the delta receptor as a model. Annu Rev Pharmacol Toxicol 1996;36:379-101.
25. Fowler CJ, Fraser GL. Mu-, delta-, kappa-opioid receptors and their subtypes: a critical review with emphasis on radioligand binding experiments. Neurochem Int 1994;24:401-426.
26. Reinscheid RK, Nothacker HP, Bourson A, et al. Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science 1995;270:792-794.
27. Meunier JC, Mollereau C, Toll L, et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 1995;377:532-535.
28. Zadina JE, Hackler L, Ge LJ, Kastin AJ. A potent and selective endogenous agonist for the mu-opiate receptor. Nature 1997;386: 499-502.
29. Nothacker HP, Reinscheid RK, Mansour A, et al. Primary structure and tissue distribution of the orphanin FQ precursor. Proc Natl Acad Sci U S A 1996;93:8677-8682.
30. Mollereau C, Simons MJ, Soularue P, et al. Structure, tissue distribution, and chromosomal localization of the prepronociceptin gene. Proc Natl Acad Sci U S A 1996;93:8666-8670.
31. Arjomand J, Evans CJ. Evidence for an alternatively spliced orphanin FQ mRNA in human fetal brain stem (abstract). Society for Neuroscience; 1997 Nov 30; New Orleans LA, p. 2318.
32. Florin S, Suaudeau C, Meunier JC, Costentin J. Orphan neuropeptide NocII, a putative pronociceptin maturation product, stimulates locomotion in mice. Neuroreport 1997;8:705-707.
33. Saito Y, Maruyama K, Saido TC, Kawashima S. N23K, a gene transiently up-regulated during neural differentiation, encodes a precursor protein for a newly identified neuropeptide nociceptin. Biochem Biophys Res Commun 1995;217:539-545.
34. Saito Y, Maruyama K, Kawano H, et al. Molecular cloning and characterization of a novel form of neuropeptide gene as a developmentally regulated molecule. J Biol Chem 1996;271: 15615-15622.
35. Saito Y, Maruyama K, Saido TC, Kawashima S. Overexpression of a neuropeptide nociceptin/orphanin FQ precursor gene, N23K/ N27K, induces neurite outgrowth in mouse NS20Y cells. J Neurosci Res 1997;48:397-406.
36. Pan YX, Xu J, Pasternak GW. Cloning and expression of a cDNA encoding a mouse brain orphanin FQ/nociceptin precursor. Biochem J 1996;315(Pt 1):11-13.
37. Houtani T, Nishi M, Takeshima H, Nukada T, Sugimoto T. Structure and regional distribution of nociceptin/orphanin FQ precursor. Biochem Biophys Res Commun 1996;219:714-719.
38. Fukuda K, Kato S, Morikawa H, Shoda T, Mori K. Functional coupling of the delta-, mu-, and kappa-opioid receptors to mitogen-activated protein kinase and arachidonate release in Chinese hamster ovary cells. J Neurochem 1996;67:1309-1316.
39. Nestler EJ, Hope BT, Widnell KL. Drug addiction: a model for the molecular basis of neural plasticity. Neuron 1993;11:995-1006.
40. Connor M, Vaughan CW, Chieng B, Christie MJ. Nociceptin receptor coupling to a potassium conductance in rat locus coeruleus neurones in vitro. Br J Pharmacol 1996;119:1614-1618.
41. Vaughan CW, Christie MJ. Increase by the ORL1 receptor (opioid receptor-like1) ligand, nociceptin, of inwardly rectifying K conductance in dorsal raphe nucleus neurones. Br J Pharmacol 1996;117:1609-1611.
42. Vaughan CW, Ingram SL, Christie MJ. Actions of the ORL1 receptor ligand nociceptin on membrane properties of rat periaqueductal gray neurons in vitro. J Neurosci 1997;17:996-1003.
43. Matthes H, Seward EP, Kieffer B, North RA. Functional selectivity of orphanin FQ for its receptor coexpressed with potassium channel subunits in Xenopus laevis oocytes. Mol Pharmacol 1996;50:447-450.
44. + (GIRK) channel. Mol Brain Res 1997;45:117-126.
45. 2+ in the SH-SY5Y human neuroblastoma cell line. Br J Pharmacol 1996;118:205-207.
46. Knoflach F, Reinscheid RK, Civelli O, Kemp JA. Modulation of voltage-gated calcium channels by orphanin FQ in freshly dissociated hippocampal neurons. J Neurosci 1996;16:6657-6664.
47. Patel HJ, Giembycz MA, Spicuzza L, Barnes PJ, Belvisi MG. Naloxone-insensitive inhibition of acetylcholine release from parasympathetic nerves innervating guinea-pig trachea by the novel opioid, nociceptin. Br J Pharmacol 1997;120:735-736.
48. Giuliani S, Maggi CA. Inhibition of tachykinin release from peripheral endings of sensory nerves by nociceptin, a novel opioid peptide. Br J Pharmacol 1996;118:1567-1569.
49. + evoked glutamate release from rat cerebrocortical slices. Br J Pharmacol 1996;119:1081-1083.
50. Neal MJ, Cunningham JR, Paterson SJ, McKnight AT. Inhibition by nociceptin of the light-evoked release of ACh from retinal cholinergic neurones. Br J Pharmacol 1997;120:1399-1400.
51. Gintzler AR, Adapa ID, Toll L, Medina VM, Wang L. Modulation of enkephalin release by nociceptin (orphanin FQ). Eur J Pharmacol 1997;325:29-34.
52. Mogil JS, Grisel JE, Reinscheid RK, Civelli O, Belknap JK, Grandy DK. Orphanin FQ is a functional anti-opioid peptide. Neuroscience 1996;75:333-337.
53. Grisel JE, Mogil JS, Belknap JK, Grandy DK. Orphanin FQ acts as a supraspinal, but not a spinal, anti-opioid peptide. Neuroreport 1996;7:2125-2129.
54. Mogil JS, Grisel JE, Zhangs G, Belknap JK, Grandy DK. Functional antagonism of mu-, delta- and kappa-opioid antinociception by orphanin FQ. Neurosci Lett 1996;214:131-134.
55. Tian JH, Xu W, Fang Y, et al. Bidirectional modulatory effect of orphanin FQ on morphine-induced analgesia: antagonism in brain and potentiation in spinal cord of the rat. Br J Pharmacol 1997;120:676-680.
56. Tian JH, Xu W, Zhang W, et al. Involvement of endogenous orphanin FQ in electroacupuncture-induced analgesia. Neuroreport 1997;8:497-500.
57. Zhu CB, Xu SF, Cao XD, et al. Antagonistic action of orphanin FQ on acupuncture analgesia in rat brain. Acupunct Electrother Res 1996;21:199-205.
58. Okuda-Ashitaka E, Tachibana S, Houtani T, et al. Identification and characterization of an endogenous ligand for opioid receptor homologue ROR-C: its involvement in allodynic response to innocuous stimulus. Mol Brain Res 1996;43:96-104.
59. Hara N, Minami T, Okuda-Ashitaka E, et al. Characterization of nociceptin hyperalgesia and allodynia in conscious mice. Br J Pharmacol 1997;121:401-408.
60. Xu XJ, Hao JX, Wiesenfeld-Hallin Z. Nociceptin or antinociceptin: potent spinal antinociceptive effect of orphanin FQ/nociceptin in the rat. Neuroreport 1996;7:2092-2094.
61. Yamamoto T, Nozaki-Taguchi N, Kimura S. Effects of intrathecally administered nociceptin, an opioid receptor-like I (ORL1) receptor agonist, on the thermal hyperalgesia induced by unilateral constriction injury to the sciatic nerve in the rat. Neurosci Lett 1997;224:107-110.
62. Yamamoto T, Nozaki-Taguchi N, Kimura S. Effects of intrathecally administered nociceptin, an opioid receptor-like(1) (ORL1) receptor agonist, on the thermal hyperalgesia induced by carageenan injection into the rat paw. Brain Res 1997;754:329-332.
63. Faber ES, Chambers JP, Evans RH, Henderson G. Depression of glutamatergic transmission by nociceptin in the neonatal rat hemisected spinal cord preparation in vitro. Br J Pharmacol 1996;119:189-190.
64. Stanfa LC, Chapman V, Kerr N, Dickenson AH. Inhibitory action of nociceptin on spinal dorsal horn neurones of the rat in vivo. Br J Pharmacol 1996;118:1875-1877.
65. Liebel JT, Swandulla D, Zeilhofer HU. Modulation of excitatory synaptic transmission by nociceptin in superficial dorsal horn neurones of the neonatal rat spinal cord. Br J Pharmacol 1997; 121:425-132.
66. Dawson-Basoa M, Gintzler AR. Nociceptin (orphanin FQ) abolishes gestational and ovarian sex steroid-induced antinociception and induces hyperalgesia. Brain Res 1997;750:48-52.
67. Kuhar MJ, Pasternak GW, editors. Analgesics: neurochemical, behavioral and clinical perspectives. New York: Raven Press; 1984.
68. Smith AP, Lee NM. Pharmacology of dynorphin. Annu Rev Pharmacol Toxicol 1988;28:123-140.
69. Rossi GC, Leventhal L, Pasternak GW. Naloxone sensitive orphanin FQ-induced analgesia in mice. Eur J Pharmacol 1996; 311(2-3):R7-R8.
70. Rothman RB. A review of the role of anti-opioid peptides in morphine tolerance and dependence. Synapse 1992;12:129-138.
71. Walker JM, Tucker DE, Coy DH, Walker BB, Akil H. Destyrosine-dynorphin antagonizes morphine analgesia. Eur J Pharmacol 1982;85:121-122.
72. Walker JM, Moises HC, Coy DH, Baldrighi G, Akil H. Nonopiate effects of dynorphin and des-Tyr-dynorphin. Science 1982; 218:1136-1138.
73. Nakazawa T, Ikeda M, Kaneko T, Yamatsu K. Analgesic effects of dynorphin-A and morphine in mice. Peptides 1985;6:75-78.
74. Friedman HJ, Jen MF, Chang JK, Lee NM, Loh HH. Dynorphin: a possible modulatory peptide on morphine or beta-endorphin analgesia in mouse. Eur J Pharmacol 1981;69:357-360.
75. Tulunay FC, Jen MF, Chang JK, Loh HH, Lee NM. Possible regulatory role of dynorphin on morphine- and beta-endorphin-induced analgesia. J Pharmacol Exp Ther 1981;219:296-298.
76. Ren MF, Lu CH, Han JS. Dynorphin-A-(1-13) antagonizes morphine analgesia in the brain and potentiates morphine analgesia in the spinal cord. Peptides 1985;6:1015-1020.
77. Xue JC, Yu YX, Han JS, Jen MF. Comparative study of the analgesic and paralytic effects induced by intrathecal dynorphin a in rats. Int J Neurosci 1995;82:83-93.
78. Spampinato S, Candeletti S. Characterization of dynorphin A-induced antinociception at spinal level. Eur J Pharmacol 1985; 110:21-30.
79. Han JS, Xie CW. Dynorphin: potent analgesic effect in spinal cord of the rat. Sci Sin [B] 1984;27:169-177.
80. Jhamandas K, Sutak M, Lemaire S. Comparative spinal analgesic action of dynorphin 1-8, dynorphinl-13, and a kappa-receptor agonist U50,488. Can J Physiol Pharmacol 1986;64:263-268.
81. Kaneko T, Nakazawa T, Ikeda M, et al. Sites of analgesic action of dynorphin. Life Sci 1983; 33(1 Suppl):661-664.
82. Long JB, Rigamonti DD, de Costa B, Rice KC, Martinez-Arizala A. Dynorphin A-induced rat hindlimb paralysis and spinal cord injury are not altered by the kappa opioid antagonist nor-binaltorphimine. Brain Res 1989;497:155-162.
83. Walker JM, Katz RJ, Akil H. Behavioral effects of dynorphin 1-13 in the mouse and rat: initial observations. Peptides 1980;1: 341-345.
84. Chahl LA, Chahl JS. Plasma extravasation induced by dynorphin-(1-13) in rat skin. Eur J Pharmacol 1986;124:343-347.
85. Hooke LP, He L, Lee NM. [Des-Tyr1]dynorphin A-(2-17) has naloxone-insensitive antinociceptive effect in the writhing assay. J Pharmacol Exp Ther 1995;73:802-807.
86. Takemori AE, Loh HH, Lee NM. Suppression by dynorphin A-(1-13) of the expression of opiate withdrawal and tolerance in mice. Eur J Pharmacol 1992;221:223-226.
87. Hooke LP, He L, Lee NM. Dynorphin A modulates acute and chronic opioid effects. J Pharmacol Exp Ther 1995;273:292-297.
88. Stevens KE, Leslie FM, Evans CJ, Belluzzi JD, Stein L. BAM-18: analgesia, hyperalgesia and locomotor effects. Neuropeptides 1988;12:21-27.
89. Nishi M, Houtani T, Noda Y, et al. Unrestrained nociceptive response and disregulation of hearing ability in mice lacking the nociceptin/orphanin FQ receptor. EMBO J 1997;16:1858-1864.
90. Zhang S, Yu L. Identification of dynorphins as endogenous ligands for an opioid receptor-like orphan receptor. J Biol Chem 1995;270:22772-22776.
91. Mathis JP, Ryan-Moro J, Chang A, Horn JS, Scheinberg DA, Pasternak GW. Biochemical evidence for orphanin FQ/nociceptin receptor heterogeneity in mouse brain. Biochem Biophys Res Commun 1997;230:462-465.
92. 91a. Shukla VK, Lemaire S. Non-opioid effects of dynorphins: possible role of the NMDA receptor. Trends Pharmacol Sci 1994; 15:420-424.
93. Wise RA. Opiate reward: sites and substrates. Neurosci Biobehav Rev 1989;13:129-133.
94. Akil H, Watson SJ, Young E, Lewis ME, Khachaturian H, Walker JM. Endogenous opioids: biology and function. Annu Rev Neurosci 1984;7:223-255.
95. Devine DP, Reinscheid RK, Monsma FJ Jr, Civelli O, Akil H. The novel neuropeptide orphanin FQ fails to produce conditioned place preference or aversion. Brain Res 1996;727:225-229.
96. Devine DP, Taylor L, Reinscheid RK, Monsma FJ Jr, Civelli O, Akil H. Rats rapidly develop tolerance to the locomotor-inhibiting effects of the novel neuropeptide orphanin FQ. Neurochem Res 1996;21:1387-1396.
97. Murphy NP, Ly HT, Maidment NT. Intracerebroventricular orphanin FQ/nociceptin suppresses dopamine release in the nucleus accumbens of anaesthetized rats. Neuroscience 1996;75:1-4.
98. Spanagel R, Herz A, Shippenberg TS. The effects of opioid peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study. J Neurochem 1990;55:1734-1740.
99. Florin S, Suaudeau C, Meunier JC, Costentin J. Nociceptin stimulates locomotion and exploratory behaviour in mice. Eur J Pharmacol 1996;317:9-13.
100. Pomonis JD, Billington CJ, Levine AS. Orphanin FQ, agonist of orphan opioid receptor ORL1, stimulates feeding in rats. Neuroreport 1996;8:369-371.
101. Stratford TR, Holahan MR, Kelley AE. Injections of nociceptin into nucleus accumbens shell or ventromedial hypothalamic nucleus increase food intake. Neuroreport 1997;8:423-426.
102. Gosnell BA, Levine AS. Stimulation of ingestive behavior by preferential and selective opioid agonists. In: Cooper SJ, Clifton PG, editors. Drug receptor subtypes and ingestive behavior. San Diego (CA): Academic Press; 1996. p. 147-166.
103. Sandin J, Georgieva J, Schott PA, Ogren SO, Terenius L. Nociceptin/orphanin FQ microinjected into hippocampus impairs spatial learning in rats. Eur J Neurosci 1997;9:194-197.
104. Morris BJ, Johnston HM. A role for hippocampal opioids in long-term functional plasticity. Trends Neurosci 1995;18:350-355.
105. Yu TP, Fein J, Phan T, Evans CJ, Xie CW. Orphanin FQ inhibits synaptic transmission and long-term potentiation in rat hippocampus. Hippocampus 1997;7:88-94.
106. Monteillet-Agius G, Fein J, Phan T, et al. Regulation and distribution of members of the opioid receptor family. Proc West Pharmacol Soc 1996;39:69-70.
107. Riedl M, Shuster S, Vulchanova L, Wang J, Loh HH, Elde R. Orphanin FQ/nociceptin-immunoreactive nerve fibers parallel those containing endogenous opioids in rat spinal cord. Neuroreport 1996;7:1369-1372.
108. Schulz S, Schreff M, Nuss D, Gramsch C, Hollt V. Nociceptin/ orphanin FQ and opioid peptides show overlapping distribution but not co-localization in pain-modulatory brain regions. Neuroreport 1996;7:3021-3025.
109. Shimohigashi Y, Hatano R, Fujita T, et al. Sensitivity of opioid receptor-like receptor ORL1 for chemical modification on nociceptin, a naturally occurring nociceptive peptide. J Biol Chem 1996;271:23642-23645.
110. Hao JX, Wiesenfeld-Hallin Z, Xu XJ. Lack of cross-tolerance between the antinociceptive effect of intrathecal orphanin FQ and morphine in the rat. Neurosci Lett 1997;223:49-52.